Oncopeptides AB (publ)

Stockholm Stock Exchange ONCO.ST

Oncopeptides AB (publ) Return on Assets (ROA) for the year ending December 31, 2023: -104.50%

Oncopeptides AB (publ) Return on Assets (ROA) is -104.50% for the year ending December 31, 2023, a -19.15% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Oncopeptides AB (publ) Return on Assets (ROA) for the year ending December 31, 2022 was -87.71%, a 73.06% change year over year.
Oncopeptides AB (publ) Return on Assets (ROA) for the year ending December 31, 2021 was -325.53%, a -93.27% change year over year.
Oncopeptides AB (publ) Return on Assets (ROA) for the year ending December 31, 2020 was -168.44%, a -125.92% change year over year.
Oncopeptides AB (publ) Return on Assets (ROA) for the year ending December 31, 2019 was -74.56%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Stockholm Stock Exchange: ONCO.ST

Oncopeptides AB (publ)

CEO	Ms. Sofia Heigis M.Sc.
IPO Date	Feb. 22, 2017
Location	Sweden
Headquarters	Vastra Tradgardsgatan 15
Employees	79
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years